Skip to content
Screener

Taysha Gene Therapies, Inc. TSHA Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$14.31M+22.4%
uniQure logo
uniQureQURE
$2.99M-23.5%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$536K-34.7%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$2.22M-32.6%
CalAmp logo
CalAmpCAMP
$384K-87.5%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$11.2M-15.6%

Other financials

Income statement

See full
Revenue--100%
Operating income-$47.3M-77.0%
Net income-$46.6M-73.5%
EPS (diluted)-$0.13-44.4%

Balance sheet

See full
Cash & equivalents$455.4M+45.6%
Total debt$56.7M-5.1%
Total equity$387.3M+55.7%
Total assets$470.4M+41.1%

Cash flow

See full
Operating cash flow-$40.4M-100%
CapEx$24.0K-93.7%
Free cash flow-$40.4M-100%

Valuation

See full
Market cap$1.89B+161%
Enterprise value$1.49B+217%
P/S343.7×+255×

Profitability

See full
Operating margin-2,792.3%-9,679pp
Net margin-2,728%-9,858pp
FCF margin-2,417%-8,925pp

Returns & leverage

See full
Return on equity-47.1%-4.0pp
Debt / equity0.1×-0.1×
Current ratio17.8×+5.3×

Where this comes from

Reported directly by Taysha Gene Therapies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed August 11, 2026. Open the filing →

Filed
Aug 11, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344610

FAQ

What is Taysha Gene Therapies, Inc.'s operating lease liabilities (current)?
Taysha Gene Therapies, Inc. (TSHA) reported operating lease liabilities (current) of $996K in Q2 2026.
How has Taysha Gene Therapies, Inc.'s operating lease liabilities (current) changed year-over-year?
Taysha Gene Therapies, Inc.'s operating lease liabilities (current) decreased by 24.9% year-over-year, from $1.33M to $996K.
What is the long-term trend for Taysha Gene Therapies, Inc.'s operating lease liabilities (current)?
Over 3 years (2022 to 2025), Taysha Gene Therapies, Inc.'s operating lease liabilities (current) has grown at a 7.4% compound annual growth rate (CAGR), from $1.2M to $1.49M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Taysha Gene Therapies, Inc.'s operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude